

## Recombinant Human PCSK9 Protein (His Tag/HA/AVI)

**Catalog Number: PKSH032945**

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

<b>Species</b>	Human
<b>Source</b>	HEK293 Cells-derived Human PCSK9 protein Gln31-Gln692(Val474Ile, Gly670Glu), with an C-terminal His & HA & Avi
<b>Calculated MW</b>	14&62 kDa
<b>Observed MW</b>	18&58-70&90-150 kDa
<b>Accession</b>	Q8NBP7
<b>Bio-activity</b>	Not validated for activity

### Properties

<b>Purity</b>	> 95 % as determined by reducing SDS-PAGE.
<b>Concentration</b>	Subject to label value.
<b>Endotoxin</b>	< 1.0 EU per µg of the protein as determined by the LAL method.
<b>Storage</b>	Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
<b>Shipping</b>	This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < -20°C.
<b>Formulation</b>	Supplied as a 0.2 µm filtered solution of 50mM HEPES, 150mM NaCl, 20% Glycerol, pH 7.4.

### Data



> 95 % as determined by reducing SDS-PAGE.

### Background

Human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is a secretory subtilase belonging to the proteinase K subfamily. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the ER; the pro domain and mature chain secrete together through noncovalent interactions. PCSK9 binds with low-density lipoprotein receptor (LDLR) and plays a major regulatory role in cholesterol homeostasis. Inhibition of PCSK9 function by preventing PCSK9/LDLR interaction is currently being explored as a means of lowering cholesterol levels. PCSK9 also binds to apolipoprotein receptor 2 (ApoER2); and play a role in the neural development.